References
Walker A, Delle Donne A, Douglas E, Spicer K, Pluim T. Novel use of dexmedetomidine for the treatment of anticholinergic toxidrome. J Med Toxicol 2014.
Dart RC, Borron SW, Caravati EM, Cobaugh DJ, Curry SC, Falk JL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med 2009;54:386–94 e1.
Rasimas JJ, Smolcic EE, Cressell A, Sachdeva K, Donovan JW. Bedside toxicologic experience with physostigmine and flumazenil. Clinical Toxicology Abstract 2010
Proudfoot A (2006) The early toxicology of physostigmine: a tale of beans, great men and egos. Toxicol Rev 25:99–138
Riker RR, Fraser GL (2001) Monitoring sedation, agitation, analgesia, neuromuscular blockade, and delirium in adult ICU patients. Seminars in respiratory and critical care medicine 22:189–98
Somani SM, Khalique A (1987) Pharmacokinetics and pharmacodynamics of physostigmine in the rat after intravenous administration. Drug metabolism and disposition: the biological fate of chemicals 15:627–33
Walker WE, Levy RC, Hanenson IB (1976) Physostigmine–its use and abuse. JACEP 5:436–9
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moore, P.W., Rasimas, J.J. & Donovan, J.W. Physostigmine is the Antidote for Anticholinergic Syndrome. J. Med. Toxicol. 11, 159–160 (2015). https://doi.org/10.1007/s13181-014-0442-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13181-014-0442-z